DEF: Quoin Pharmaceuticals Seeks Shareholder Approval for Massive Capital Increase and New Equity Plan Amidst Continued Losses

Quoin Pharmaceuticals Ltd. has called its 2025 Annual General Meeting to approve a significant increase in authorized share capital, a new executive compensation policy, and a new equity incentive plan, following a period of consistent net losses and a substantial decline in shareholder value.

Summary

• The 2025 Annual General Meeting of Shareholders will be held on Thursday, August 21, 2025, at 12 p.m. US Eastern Time in Philadelphia, PA.
• The record date for determining shareholders entitled to vote is July 16, 2025.
• Shareholders will vote on seven proposals, including the re-election of seven directors: Dr. Michael Myers, Denise Carter, Joseph Cooper, James Culverwell, Dr. Dennis H. Langer, Natalie Leong, and Michael Sember.
• A key proposal seeks to amend the Company's Articles of Association to increase the authorized ordinary share capital from 100,000,000 shares to 5,000,000,000 shares.
• Shareholders will also vote on approving a new Compensation Policy for Executive Officers and Directors and the Quoin Pharmaceuticals Ltd. 2025 Equity Incentive Plan.
• The 2025 Equity Incentive Plan proposes reserving 3,000,000 shares for awards, with an automatic annual increase of up to 15% of outstanding shares from 2026 to 2035.
• Changes to the non-employee directors' compensation program are proposed, including increasing the annual retainer to up to $125,000 and allowing payment in options.
• Specific option grants to non-employee directors James Culverwell (13,682 ADSs), Dr. Dennis H. Langer (13,682 ADSs), and Natalie Leong (4,105 ADSs) in lieu of a portion of their 2025 cash retainer require shareholder approval.
• CBIZ CPAs P.C. is proposed to be appointed as the independent registered public accounting firm until the next annual general meeting, following Marcum LLP's resignation on March 18, 2025.
• As of July 16, 2025, there were 20,585,830 ordinary shares issued and outstanding, represented by 588,166 ADSs (each ADS represents 35 ordinary shares).
• A 1-for-35 reverse split of the issued and outstanding ADSs became effective on April 9, 2025.
• The company reported net losses of $9.0 million for the fiscal year ended December 31, 2024, $8.7 million for 2023, and $9.4 million for 2022.
• Total Shareholder Return (TSR) for a $100 investment at December 31, 2021, declined to $0.26 by December 31, 2024.
• Dr. Michael Myers' (CEO) total compensation for 2024 was $1,406,801, and Denise Carter's (COO) was $1,211,262.
• Gordon Dunn (CFO) will mutually separate from the company later this year, continuing in his role until a successor is appointed.
• Outstanding non-interest-bearing indebtedness to Dr. Michael Myers and Ms. Carter from prior unpaid compensation was approximately $1,659,000 and $1,265,000, respectively, as of December 31, 2024.
• The company completed a December 2024 offering, raising approximately $6.8 million gross ($5.8 million net), with management participating for $600,000.

Sentiment

Score: 3

Explanation: The document outlines necessary corporate governance actions and plans for future capital raises, which are essential for a development-stage biotech. However, the consistent net losses, significant decline in Total Shareholder Return, and the need for substantial share capital increase (implying future dilution) indicate ongoing financial challenges and poor past performance, leading to a negative overall sentiment for investors.

Positives

• The Board recommends approval of all proposals, indicating internal alignment on strategic and governance matters.
• The proposed 2025 Equity Incentive Plan aims to attract, retain, and motivate employees, directors, officers, and consultants, which is crucial for a development-stage pharmaceutical company.
• Changes to the non-employee directors' compensation program are designed to ensure competitive compensation, aiding in the attraction and retention of high-quality independent directors.
• Management and directors participated in the December 2024 offering, demonstrating some level of commitment and alignment of interests with shareholders.

Negatives

• The company has reported consistent net losses: $9.0 million in 2024, $8.7 million in 2023, and $9.4 million in 2022, indicating ongoing financial challenges and a lack of profitability.
• Total Shareholder Return (TSR) has significantly declined, with a $100 investment at December 31, 2021, dropping to $0.26 by December 31, 2024, reflecting poor stock performance.
• The proposed increase in authorized ordinary share capital from 100 million to 5 billion shares is substantial and signals a high potential for significant future dilution for existing shareholders.
• Outstanding indebtedness to the CEO ($1,659,000) and COO ($1,265,000) from prior unpaid compensation highlights past financial constraints and potential liquidity issues.
• The mutual separation of the Chief Financial Officer, Gordon Dunn, introduces a period of management transition.

Risks

• **Share Dilution**: The proposed increase in authorized ordinary share capital from 100,000,000 to 5,000,000,000 shares could lead to substantial future dilution of existing shareholders' percentage equity ownership, voting power, and potentially negatively impact the market price of ADSs.
• **Anti-takeover Effects**: The increased authorized shares could be used as an anti-takeover mechanism, potentially deterring unsolicited takeovers or making changes in control more difficult, which might limit opportunities for shareholders to dispose of their shares at a premium.
• **Financial Performance**: The company's consistent net losses ($9.0 million in 2024, $8.7 million in 2023, $9.4 million in 2022) indicate ongoing operational challenges and raise concerns about future profitability and sustainability.
• **Reliance on Equity Financing**: The explicit need for additional authorized shares to pursue 'future equity financing opportunities' suggests continued reliance on capital raises, which will likely result in further dilution for existing shareholders.
• **Management Transition**: The mutual separation of the Chief Financial Officer, Gordon Dunn, creates uncertainty during the search for and integration of a successor.
• **Tax Consequences of Equity Awards**: The company disclaims responsibility for adverse tax consequences to grantees if equity awards do not qualify for particular tax treatments, placing this risk solely on the grantee.

Future Outlook

The company anticipates seeking future equity financing opportunities and will evaluate commercial partnership opportunities. The new 2025 Equity Incentive Plan is designed to incentivize long-term performance and retention of key personnel.

Management Comments

• "We look forward to seeing you at the Annual Meeting."
• "The availability of additional ordinary shares for issuance is, in management's view, prudent and will afford us flexibility in acting upon financing transactions to strengthen our financial position and/or commercial partnership opportunities that may arise."
• "We believe that the Authorized Ordinary Share Increase will help ensure that we have sufficient authorized shares available for issuance to allow us to pursue equity financings if the Board of Directors determines that it would be in our best interests based on our working capital needs and prevailing market conditions."
• "The Board believes that Quoin's current leadership structure is appropriate for Quoin as it makes the best use of Dr. Myers' extensive experience in the life sciences industry, skills, expertise, as well as knowledge of Quoin's business and industry. It also fosters real-time communication between management and the Board."
• "The proposed executive compensation framework under the New Compensation Policy will be effective in achieving our objectives of: To closely align the interests of the executive officers with those of the Company's shareholders in order to enhance shareholder value; To align a significant portion of the executive officers' compensation with the Company's short and long-term goals and performance; To provide the executive officers with a structured compensation package, including competitive salaries, performance-motivating cash and equity incentive programs and benefits, and to be able to present to each executive officer an opportunity to advance in a growing organization; To strengthen the retention and the motivation of executive officers in the long-term; To provide appropriate awards in order to incentivize superior individual excellence and corporate performance; and To maintain consistency in the way executive officers are compensated."

Industry Context

Quoin Pharmaceuticals Ltd. operates in the drug delivery and specialty pharmaceutical sectors, a highly competitive and capital-intensive industry. The company's consistent net losses and reliance on equity financing are common characteristics of development-stage biotechnology and pharmaceutical firms, which typically require substantial and sustained funding for research, development, and regulatory approvals before achieving profitability. The focus on equity incentives and robust corporate governance structures is standard practice to attract and retain talent in this specialized field.

Management Changes

Corporate Governance

Related Party Transactions

• Outstanding non-interest-bearing indebtedness to Dr. Michael Myers of approximately $1,659,000 and to Ms. Denise Carter of approximately $1,265,000 as of December 31, 2024, stemming from accrued unpaid compensation prior to the Merger. The company repaid $300,000 to each in 2023 and 2024.
• Estimated liability of $1,146,000 as of December 31, 2024 and 2023, to three 2020 Noteholders, including directors Messrs. Langer and Culverwell, from promissory notes converted into ADSs in 2021.
• Dr. Myers, Ms. Carter, Mr. Dunn, and Mr. Culverwell collectively purchased approximately $600,000 worth of ordinary shares and accompanying warrants in the December 2024 Offering, on the same terms as other public purchasers.

Stakeholder Impact

• **Shareholders**: Face significant potential dilution from the proposed 50-fold increase in authorized share capital, which could negatively impact their ownership percentage, voting power, and share price. Historical poor TSR indicates a negative impact on shareholder value. Shareholders have a critical role in approving key governance and compensation proposals.
• **Employees**: The new Equity Incentive Plan and Compensation Policy are designed to attract, retain, and motivate employees and executive officers through competitive salaries, bonuses, and equity awards, potentially fostering a more engaged workforce.
• **Management/Directors**: Compensation programs are structured to incentivize and retain key personnel, aligning their interests with company performance. The mutual separation of the CFO indicates a change for this specific executive, potentially impacting team dynamics.
• **Creditors**: The company's consistent net losses and outstanding indebtedness to executives may raise concerns about financial health, though the recent capital raise provides some liquidity.

Next Steps

• Hold the Annual General Meeting of Shareholders on August 21, 2025, to vote on all proposed resolutions.
• Company management will be available at the Annual Meeting to discuss the financial statements for the fiscal year ended December 31, 2024.
• Final voting results will be published in a current report on Form 8-K within four business days after the Annual Meeting.
• Gordon Dunn (CFO) will continue in his role until his successor is appointed, followed by a mutual separation.
• The 2025 Equity Incentive Plan will have an automatic annual increase in shares available starting January 1, 2026, through January 1, 2035.

Key Dates

Recommendation

Keywords

Quoin Pharmaceuticals, SEC Filing, Proxy Statement, Annual General Meeting, Share Capital Increase, Equity Incentive Plan, Executive Compensation, Corporate Governance, Share Dilution, Net Loss, Total Shareholder Return, Biotechnology, Pharmaceuticals, Risk Management, Nasdaq